• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.07% Nasdaq Up0.32%

    More On GILD.MX



    News & Info


    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Gilead Sciences Inc. (GILD.MX)

    1,796.25 Down 15.68(0.87%) Aug 28, 4:09PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Gilead Sciences Inc.
    333 Lakeside Drive
    Foster City, CA 94404
    United States - Map
    Phone: 650-574-3000
    Fax: 650-578-9264
    Website: http://www.gilead.com

    Index Membership:N/A
    Full Time Employees:7,000

    Business Summary 

    Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. The company’s products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with Bristol-Myers Squibb Company, Janssen R&D Ireland, and Japan Tobacco Inc. to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Gilead Sciences Inc.

    Key Executives 
    Dr. John C. Martin Ph.D., 63
    Chairman and Chief Exec. Officer
    Dr. John F. Milligan Ph.D., 54
    Pres and Chief Operating Officer
    Ms. Robin L. Washington , 52
    Chief Financial Officer and Exec. VP
    Dr. Norbert W. Bischofberger Ph.D., 59
    Chief Scientific Officer and Exec. VP of R&D
    Mr. Gregg H. Alton , 49
    Exec. VP of Corp. & Medical Affairs and Sec.
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in MXN.